World Hepatitis Day 2026—Let's break it down

Image

FISPGHAN campaign World Hepatitis Day
(July 28, 2026)

Image

FISPGHAN Statement on World Hepatitis Day

On the occasion of World Hepatitis Day, the Federation of International Societies for Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN) joins the global community in reaffirming our commitment to eliminate viral hepatitis as a public health threat and to ensure that every child has the opportunity to grow up free from viral hepatitis and its long-term consequences.

Despite substantial progress over recent decades, viral hepatitis continues to be a major cause of preventable illness and death worldwide. It affects millions of children and adolescents around the world. Many remain undiagnosed, untreated, or lack access to preventive and health care services. Consequently, they face a high lifetime risk of chronic liver disease, cirrhosis, and liver cancer. Elimination of viral hepatitis by 2030 cannot be achieved without a resolute, unwavering focus on the pediatric population.

Hepatitis B: Breaking the Cycle of Mother-to-Child Transmission

Infants infected with hepatitis B virus during birth or early childhood face a 90% risk of developing chronic infection, predisposing them to cirrhosis and liver cancer later in life. FISPGHAN strongly supports comprehensive, evidence-based strategies to eliminate mother-to-child transmission and early childhood infection, in accordance with WHO recommendations and national policies.

These strategies include:

  • ·       Universal maternal hepatitis B screening during pregnancy

  • Appropriate antiviral therapy for pregnant women when indicated.
  • Timely hepatitis B birth-dose vaccination within 24 hours for all newborns to ensure immediate protection even where maternal screening is delayed, undocumented, or missed.
  • ·       Completion of the full hepatitis B vaccination series for all infants to provide long-term protection.

Hepatitis C: A Curable Disease

The availability of highly effective direct-acting antiviral agents that can cure hepatitis C in children as young as 3 years of age has transformed the management of pediatric hepatitis C. All children and adolescents living with hepatitis C should have timely access to diagnosis, appropriate clinical care, and curative treatment in accordance with current recommendations.

Find Every Child

Many children with chronic hepatitis B or hepatitis C have no symptoms until liver disease has progressed. Earlier diagnosis enables appropriate monitoring, timely treatment when indicated, and prevention of further transmission. FISPGHAN encourages healthcare professionals to increase awareness, identify children at risk, and ensure timely access to appropriate evaluation and care.

Image

Call to action

On this World Hepatitis Day, FISPGHAN calls upon governments, healthcare providers, professional societies, public health agencies, and international partners to work together to ensure equitable access to hepatitis prevention, diagnosis, and care for all children and that no child is left behind in the global effort to eliminate viral hepatitis.

We call for collective action to:

·       Strengthen programs to prevent mother-to-child transmission of hepatitis B through universal antenatal screening, antiviral therapy for eligible pregnant women, and timely hepatitis B birth-dose vaccination within 24 hours.

·       Strengthen national immunization programs to achieve and sustain high hepatitis B vaccination coverage by ensuring equitable access to timely birth-dose vaccination, completion of the infant vaccination series, and catch-up vaccination for unvaccinated children and adolescents.

·       Expand hepatitis B and hepatitis C testing and early diagnosis for children and adolescents at risk of infection, including appropriate follow-up of infants born to infected mothers.

·       Ensure equitable access to appropriate monitoring and treatment for children with chronic hepatitis B, and to curative therapy for hepatitis C.

·       Promote safe healthcare practices to prevent the transmission of viral hepatitis.

·       Raise awareness of viral hepatitis in children among healthcare professionals, families, educators, communities, and policymakers, and combat stigma.

·       Strengthen research, education, and international collaboration to accelerate progress towards the WHO goal of eliminating viral hepatitis as a public health threat by 2030.

Featured Resources

Quick guide to Hepatitis C for HCPs
Quick guide to Hepatitis C for the public
Quick guide to Hepatitis B for the public

Who should be tested?

For healthcare professionals:

  • All pregnant women should be tested for hepatitis B to allow timely prevention of mother-to-child transmission. Hepatitis C testing during pregnancy should follow national recommendations, epidemiology and individual risk assessment.
  • Infants born to mothers with hepatitis B or C require appropriate prophylaxis, follow-up and testing according to their type of exposure.
  • Children and adolescents with suspected liver disease should be evaluated, particularly when they have jaundice, unexplained abnormal liver tests, hepatomegaly, persistent fatigue or other signs of acute or chronic hepatitis.
  • Testing for hepatitis B and C should be considered after exposure to potentially infected blood, unsafe injections or procedures, unscreened blood products, haemodialysis, shared injecting equipment, or tattoos and piercings performed with non-sterile equipment.
  • Children and adolescents who are household or sexual contacts of someone with hepatitis B should be assessed and vaccinated when appropriate.
  • People who test positive for hepatitis B should also be evaluated for hepatitis D, particularly when clinically indicated or according to local epidemiology.
  • Testing for hepatitis A or E is generally diagnostic rather than routine and should be considered in patients with acute hepatitis, relevant travel or food and water exposure, or during suspected outbreaks.
Image